Momenta Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
MNTA Momenta Pharmaceuticals Inc
LMT Lockheed Martin Corp
POL PolyOne Corp
HAS Hasbro Inc
JBLU JetBlue Airways Corp
CDNS Cadence Design Systems Inc
IVAC Intevac Inc
HLIT Harmonic Inc
MPWR Monolithic Power Systems Inc
MXIM Maxim Integrated Products Inc

Health Care : Biotechnology | Small Cap BlendCompany profile

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Day's Change
0.22 (1.53%)
B/A Size
Day's High
Day's Low

Today's volume of 103,287 shares is on pace to be much lighter than MNTA's 10-day average volume of 320,501 shares.


UPDATE: CBS, Viacom, WarnerMedia will reportedly stop airing e-cigarette ads

7:24 am ET September 19, 2019 (MarketWatch)

By Mike Murphy

Networks ban commercials amid outbreak of vaping-related breathing illnesses

In another blow to the vaping industry, CBS Corp., WarnerMedia and Viacom Inc. reportedly said Wednesday that they will no longer air commercials for electronic cigarettes.

The ad bans come after New York ( Michigan ( banned the sale of flavored e-cigarettes and amid a federal investigation into a deadly surge of breathing illnesses related to vaping.

CNBC first reported ( network bans Wednesday, which come after the Daily Beast reported Friday ( CNN -- a unit of AT&T's (T) WarnerMedia -- would stop airing commercials for vaping products. The New York Times ( confirmed CNBC's report.

WarnerMedia networks include TBS and TNT, and Viacom networks include MTV and Comedy Central.

"Given warnings from the CDC, the AMA and the American Lung Association to consumers, our company has revised its policies regarding e-cigarette advertising, and will no longer accept advertising for this category," a WarnerMedia spokesperson told CNBC.

A CBS (CBS) spokesperson told CNBC that it would no longer allow vaping ads, and a Viacom (VIA) spokesperson said it will "no longer air ads in this category effective immediately." (The networks agreed last month to merge (

Cigarette ads have been banned on TV and radio since 1970.

More than 20 TV networks have run commercials for e-cigarette giant Juul Labs in the past two weeks, CNBC reported, with about $2.2 million spent on 900 airings.

San Francisco-based Juul did not immediately respond to MarketWatch's request for comment.

Federal health officials have recently identified at least seven deaths and around 400 cases of severe pulmonary diseases ( among people who use e-cigarettes or other vaping devices. There has been speculation that the illnesses were caused by devices that had been modified on the street.

The Trump administration has also announced it will crack down on vaping (, targeting flavored e-cigarettes that appeal to youths.

Juul has said it would comply with any new restrictions. "We strongly agree with the need for aggressive category-wide action on flavored products," the company said in a statement ( "We will fully comply with the final FDA policy when effective."

Earlier this month, the Federal Drug Administration accused Juul of illegally marketing its products ( safer than cigarettes.

Juul had an estimated market value of about $38 billion ( as of 2018, but CNBC reported recently that its value has fallen sharply ( In December 2018, cigarette seller Altria Group Inc.(MO) paid $13 billion for a 35% stake in Juul (

-Mike Murphy; 415-439-6400;

(END) Dow Jones Newswires

September 19, 2019 07:24 ET (11:24 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.